Investor Relations and Corporate Communications
United States of America
Robert Doody Jr. joined Idera as Vice President of Investor Relations and Corporate Communications in December 2014. Previously, Mr. Doody served as ViroPharma Incorporated’s Director of Investor Relations from May 2006 to January 2014. During his tenure at ViroPharma, the company was routinely recognized for excellence in investor relations. Mr. Doody began his communications career with Dorland Sweeney Jones, a health care public relations firm in Philadelphia. Mr. Doody earned his Bachelor of Arts degree in communications from Rowan University in 2002 after having served honorably in the United States Navy.
company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA.